2024
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1070-1082. PMID: 38973729, DOI: 10.1002/acr.25347.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1051-1069. PMID: 38973731, DOI: 10.1002/acr.25348.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1201-1213. PMID: 38973714, DOI: 10.1002/art.42860.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1182-1200. PMID: 38978310, DOI: 10.1002/art.42861.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendationsIs yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areasRegional European genetic ancestry predicts type I interferon level and risk of severe viral infection
Nln I, Shum J, Ghodke-Puranik Y, Tipon R, Triese D, Amin S, Makol A, Osborn T, Chowdhary V, Thanarajasingam U, Wampler Muskardin T, Oke V, Gunnarsson I, Zickert A, Zervou M, Boumpas D, Svenungsson E, Goulielmos G, Niewold T. Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection. QJM 2024, hcae052. PMID: 38530799, DOI: 10.1093/qjmed/hcae052.Peer-Reviewed Original ResearchType I IFN levelsViral infection outcomesI interferonLupus patientsEuropean genetic ancestryInfection outcomesAnti-viral cytokinesSevere viral infectionsType I interferon levelsHost genetic factorsRisk of severe viral infectionsSevere organ failureI interferon levelsType I IFNType I interferonVirus prior to infectionViral hepatitisOrgan failureGenetic testingViral infectionI IFNOutcome dataHost defenseGenetic factorsGenetic ancestry
2023
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Baker H, Fine R, Suter F, Allore H, Hsiao B, Chowdhary V, Lavelle E, Chen P, Hintz R, Suter L, Danve A. Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs. Arthritis Care & Research 2023 PMID: 37382043, DOI: 10.1002/acr.25181.Peer-Reviewed Original ResearchBest practice advisoryHepatitis B virusAutoimmune rheumatic diseasesBPA implementationSynthetic disease-modifying antirheumatic drugsDisease-modifying antirheumatic drugsHepatitis C virus infectionHepatitis B surface antigenC virus infectionUse of biologicsB surface antigenQuality improvement initiativesElectronic health recordsEligible patientsAntirheumatic drugsRheumatic diseasesRheumatology practiceSociety guidelinesB virusPractice advisoryComputerized decision support systemVirus infectionRoutine screeningPatient screeningPatients
2018
TD-08 High type I interferon activity is associated with active class III/IV lupus nephritis in european-american lupus patients independent of anti-dsDNA antibodies
Iwamoto T, Dorschner J, Jensen M, Vsetecka D, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold T. TD-08 High type I interferon activity is associated with active class III/IV lupus nephritis in european-american lupus patients independent of anti-dsDNA antibodies. 2018, a75.2-a76. DOI: 10.1136/lupus-2018-lsm.127.Peer-Reviewed Original ResearchFRI0371 Clinical characteristics and outcome of isolated lupus nephritis
Bugdayli K, Chowdhary V, Crowson C, Zand L, Alexander M, Cornell L. FRI0371 Clinical characteristics and outcome of isolated lupus nephritis. Annals Of The Rheumatic Diseases 2018, 77: 720. DOI: 10.1136/annrheumdis-2018-eular.6053.Peer-Reviewed Original ResearchExtra-renal manifestationsLupus nephritisSystemic lupus erythematosusAntinuclear antibodiesClinical manifestationsEnd-stage renal diseaseStandardised data collection formClass III nephritisPartial renal responseRenal biopsy databasePositive antinuclear antibodyAnti-dsDNA antibodiesMajority of patientsExtractable nuclear antigensImmune complex glomerulonephritisData collection formMean C3SLICC criteriaLast followMycophenolate mofetilRenal involvementRenal transplantClinical characteristicsLaboratory featuresPartial responsePS1:1 High type i interferon activity is associated with active class 3/4 lupus nephritis in european-american lupus patients independent of anti-dsdna antibodies
Iwamoto T, Dorschner J, Jensen M, Vsetecka D, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold T. PS1:1 High type i interferon activity is associated with active class 3/4 lupus nephritis in european-american lupus patients independent of anti-dsdna antibodies. 2018, a32.1-a32. DOI: 10.1136/lupus-2018-abstract.50.Peer-Reviewed Original Research
2017
10 Single cell expression quantitative trait LOCI (EQTL) analsis of established lupus-risk loci in patient monocytes
Ghodke-Puranik Y, Zhongbo J, Fan W, Jensen M, Dorschner J, Vsetecka D, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold T. 10 Single cell expression quantitative trait LOCI (EQTL) analsis of established lupus-risk loci in patient monocytes. Lupus Science & Medicine 2017, 4: a6. DOI: 10.1136/lupus-2017-000215.10.Peer-Reviewed Original ResearchCell typesFluidigm C1 systemDifferent cellular eventsRelated cell typesSLE risk lociDifferent cell typesEQTL associationsLoci interactEQTL analysisGene expressionMajor unanswered questionSingle-cell captureCellular eventsLoci influenceSame SNPLociPleiotropic effectsGenesEQTLsSPP1SNPsC1 systemLimited overlapImmune cell typesImmune system function
2016
GG-06 Single cell gene expression studies in lupus patient monocytes reveal novel patterns reflecting disease activity, interferon, and medical treatment
Jin Z, Fan W, Jensen M, Dorschner J, Vsetecka D, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold T. GG-06 Single cell gene expression studies in lupus patient monocytes reveal novel patterns reflecting disease activity, interferon, and medical treatment. Lupus Science & Medicine 2016, 3: a30. DOI: 10.1136/lupus-2016-000179.58.Peer-Reviewed Original ResearchNon-classical monocytesSLE patientsDisease activityClassical monocytesPatients' monocytesCell gene expressionAnti-dsDNA titersHigh disease activityHigher IFN scoresSLE patient groupAnti-inflammatory genesMonocyte gene expressionPrednisone useGene expressionMedication useClinical featuresInterferon signatureC3 complementIFN scorePatient groupImmunologic characteristicsUnsupervised hierarchical clusteringMedical treatmentPatientsIncidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria
Ungprasert P, Sagar V, Crowson C, Amin S, Makol A, Ernste F, Osborn T, Moder K, Niewold T, Maradit-Kremers H, Ramsey-Goldman R, Chowdhary V. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. Lupus 2016, 26: 240-247. PMID: 27365370, PMCID: PMC5201452, DOI: 10.1177/0961203316657434.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusACR-97SLICC-12Lupus erythematosusSystemic Lupus International Collaborating Clinics classification criteriaSystemic Lupus International Collaborating Clinics (SLICC) groupClassification criteriaIncidence of lupusIncident SLE patientsRenal-limited diseaseSLICC-12 criteriaRochester Epidemiology ProjectACR classification criteriaPopulation-based cohortOlmsted CountyMedian durationSLE patientsAdjusted incidenceAmerican CollegeClinic groupHigh incidenceImmunologic criteriaNeurologic criteriaPatientsIncidenceID: 135: SINGLE CELL GENE EXPRESSION STUDIES IN LUPUS MONOCYTES REVEAL A UNIQUE ANTII-INFLAMMATORY NON-CLASSICAL MONOCYTE POPULATION ASSOCIATED WITH CLINICAL QUIESCENCE
Jin Z, Jensen M, Dorschner J, Vsetecka D, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold T, Fan W. ID: 135: SINGLE CELL GENE EXPRESSION STUDIES IN LUPUS MONOCYTES REVEAL A UNIQUE ANTII-INFLAMMATORY NON-CLASSICAL MONOCYTE POPULATION ASSOCIATED WITH CLINICAL QUIESCENCE. Journal Of Investigative Medicine 2016, 64: 977. DOI: 10.1136/jim-2016-000120.138.Peer-Reviewed Original Research
2015
Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil
Ungprasert P, Chowdhary V, Davis M, Makol A. Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil. Lupus 2015, 25: 427-430. PMID: 26537421, DOI: 10.1177/0961203315615221.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAutoimmune myelofibrosisLupus erythematosusBullous skin lesionsPresenting manifestationPeripheral destructionHematological abnormalitiesSkin lesionsMofetilErythematosusPancytopeniaMyelofibrosisManifestationsLeucopeniaThrombocytopeniaAnemiaGlucocorticoidsLesionsAbnormalitiesID: 209 Single cell interferon signatures in lupus patient monocytes reveal a differential impact of interferon signaling between monocyte subtypes
Jin Z, Fan W, Jensen M, Dorschner J, Vsetecka D, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold T. ID: 209 Single cell interferon signatures in lupus patient monocytes reveal a differential impact of interferon signaling between monocyte subtypes. Cytokine 2015, 76: 102-103. DOI: 10.1016/j.cyto.2015.08.213.Peer-Reviewed Original ResearchSystemic lupus erythematosusHigher IFN scoresClassical monocytesIFN scoreI interferonPatients' monocytesCD16 expressionEffects of IFNHuman systemic lupus erythematosusNon-classical subtypesPrimary pathogenic factorImmune cell populationsNon-classical monocytesCell populationsSingle immune cellsType I interferonPatient blood samplesSLE patientsLupus erythematosusMonocyte subtypesInflammatory mediatorsIFN signatureImmune cellsPathogenic factorsBlood samplesAB0539 Risk of Cardiovascular Events in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study
Singh A, Crowson C, Davis M, Maradit-Kremers H, Matteson E, Chowdhary V. AB0539 Risk of Cardiovascular Events in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study. Annals Of The Rheumatic Diseases 2015, 74: 1080. DOI: 10.1136/annrheumdis-2015-eular.4318.Peer-Reviewed Original ResearchCutaneous lupus erythematosusSystemic lupus erythematosusPopulation-based cohortCardiovascular eventsCardiovascular diseaseLupus erythematosusCumulative incidenceRisk factorsDiagnosis of CLESubtypes of CLERisk of CVDPositive antinuclear antibodyIndependent risk factorSex-matched subjectsKaplan-Meier methodMedical record reviewSex-matched cohortChronic inflammatory diseaseSex-matched controlsComplex gene-environment interactionsMedian ESRAntinuclear antibodiesSystemic inflammationRecord reviewMyocardial infarctionTHU0329 Risk of Cancer is not Increased in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study
Singh A, Crowson C, Davis M, Maradit-Kremers H, Matteson E, Chowdhary V. THU0329 Risk of Cancer is not Increased in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study. Annals Of The Rheumatic Diseases 2015, 74: 314. DOI: 10.1136/annrheumdis-2015-eular.4320.Peer-Reviewed Original ResearchCutaneous lupus erythematosusSystemic lupus erythematosusPopulation-based cohortNon-melanoma skin cancerSex-matched subjectsRisk of malignancyLupus erythematosusIndex dateCumulative incidenceDiagnosis of CLESubtypes of CLESkin cancerSystemic immune dysregulationPositive antinuclear antibodyChronic autoimmune diseaseKaplan-Meier methodMedical record reviewSex-matched cohortCLE subjectsImmunomodulatory medicationsMedian ESRCLE patientsDiagnosis dateAntinuclear antibodiesImmune dysregulationTHU0372 Incidence of Systemic Lupus Erythematosus (SLE) in a Population Based Cohort Using 1982, Revised 1997 ACR and 2012 SLICC Criteria
Sagar V, Crowson C, Amin S, Makol A, Ernste F, Osborn T, Moder K, Niewold T, Maradit-Kremers H, Chowdhary V. THU0372 Incidence of Systemic Lupus Erythematosus (SLE) in a Population Based Cohort Using 1982, Revised 1997 ACR and 2012 SLICC Criteria. Annals Of The Rheumatic Diseases 2015, 74: 330. DOI: 10.1136/annrheumdis-2015-eular.4180.Peer-Reviewed Original ResearchSystemic lupus erythematosusIncidence of SLESLICC criteriaACR criteriaLupus erythematosusSystemic Lupus International Collaborating Clinics (SLICC) criteriaIncident SLE casesDrug-induced lupusSLE classification criteriaSystemic autoimmune diseasePopulation Based CohortUS white populationClassification criteriaHeterogeneous clinical phenotypesClinic criteriaCutaneous lupusPositive ANASLE criteriaOverall incidenceIncident casesPhysician diagnosisAutoimmune diseasesSLE casesMale ratioAmerican CollegeTHU0022 Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes
Jin Z, Fan W, Jensen M, Dorschner J, Vsetecka D, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold T. THU0022 Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes. Annals Of The Rheumatic Diseases 2015, 74: 200. DOI: 10.1136/annrheumdis-2015-eular.5326.Peer-Reviewed Original ResearchSystemic lupus erythematosusHigher IFN scoresClassical monocytesIFN scoreI interferonSLE patientsCD16 expressionEffects of IFNHuman systemic lupus erythematosusNon-classical subtypesPrimary pathogenic factorImmune cell populationsNon-classical monocytesCell populationsSingle immune cellsType I interferonPatient blood samplesLupus erythematosusMonocyte subtypesInflammatory mediatorsInterferon signatureIndividual monocytesPatients' monocytesIFN signatureImmune cells